ESMOEuropean
SN BioScience released a result of the first clinical trial on Nanoparticle-based anticancer therapy at ESMO(European Society for Medical Oncology) – beragampengetahuan – Beragampengetahuan
SN Bioscience (CEO Park Yung-hwan) released the phase 1 clinical trial result on SNB-101, a new anticancer medicine pipeline, at the ESMO Congress 2023 held in Madrid, Spain, from Oct 20 to 24. The phase 1 clinical trial of 21 patients with solid cancer was conducted to assess the efficacy and safety of the monotherapy […]